$1.47
1.17% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US7602731025
Symbol
RPTX
Sector
Industry

Repare Therapeutics Inc Stock price

$1.47
+0.04 2.59% 1M
-0.30 17.12% 6M
+0.16 11.98% YTD
-2.45 62.58% 1Y
-29.33 95.24% 5Y
-29.33 95.24% 10Y
-29.33 95.24% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
+0.02 1.17%
ISIN
US7602731025
Symbol
RPTX
Sector
Industry

Key metrics

Market capitalization $62.92m
Enterprise Value $-61.31m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.52
EV/Sales (TTM) EV/Sales -57.30
P/S ratio (TTM) P/S ratio 58.81
P/B ratio (TTM) P/B ratio 0.50
Revenue growth (TTM) Revenue growth -98.91%
Revenue (TTM) Revenue $1.07m
EBIT (operating result TTM) EBIT $-130.56m
Free Cash Flow (TTM) Free Cash Flow $-117.58m
Cash position $124.23m
EPS (TTM) EPS $-3.01
P/E forward negative
Short interest 1.93%
Show more

Is Repare Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Repare Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Repare Therapeutics Inc forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Repare Therapeutics Inc forecast:

Buy
100%

Financial data from Repare Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1.07 1.07
99% 99%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 29 29
15% 15%
2,684%
- Research and Development Expense 103 103
23% 23%
9,649%
-128 -128
87% 87%
-11,959%
- Depreciation and Amortization 2.61 2.61
29% 29%
244%
EBIT (Operating Income) EBIT -131 -131
85% 85%
-12,202%
Net Profit -128 -128
180% 180%
-11,974%

In millions USD.

Don't miss a Thing! We will send you all news about Repare Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Repare Therapeutics Inc Stock News

Neutral
Business Wire
about one month ago
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2025. “During the first quarter of 2025 we continued our efforts to create long-term value for our shareholders via partnering and by advancing our novel pipeline pro...
Neutral
Business Wire
about one month ago
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that it has out-licensed its discovery platforms, including certain platform and program intellectual property, to DCx Biotherapeutics Corporation (“DCx”), a newly-launched Canadian biotechnology company developing next generation...
Neutral
Business Wire
about one month ago
VANCOUVER--(BUSINESS WIRE)--DCx Biotherapeutics Corporation (“DCx”) today announced an agreement with Repare Therapeutics Inc. (“Repare”) (NASDAQ: RPTX) to (i) in-license Repare's discovery platform including certain program intellectual property, (ii) retain talent, (iii) acquire lease rights to laboratory facilities in Montreal and (iv) acquire laboratory equipment (the “Transaction”). Combin...
More Repare Therapeutics Inc News

Company Profile

Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using synthetic lethality approach in Canada. It provides SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The company's lead product candidate is RP-3500 a potent and selective oral small molecule inhibitor of ATR for the treatment of tumors with mutations in ataxia-telangiectasia mutated kinase. It also develops CCNE1-SL, a proprietary drug discovery program for tumors with amplification of CCNE1; and polymerase theta inhibitor. The company was founded in 2016 and is headquartered in St. Laurent, Canada.

Head office Canada
CEO Steve Forte
Employees 129
Founded 2016
Website www.reparerx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today